News Update: MSD's $9.2bn deal for flu biotech Cidara confirmed MSD has signed a $9.2 billion takeover deal for Cidara that will bolt on a universal flu prevention candidate in phase 3.
News Novartis says novel drug could counter malaria resistance Novartis has reported what looks like another big step forward in the treatment of malaria, as a drug with a novel mechanism hits the mark in phase 3.
News Moderna drops mRNA jab for CMV after phase 3 fail Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital CMV infections, once touted as a future blockbuster.
News Enanta weakens on RSV treatment trial readout Shares in Enanta Pharma were sliding this morning after it reported results of a phase 2b trial of its RSV antiviral zelicapavir.
News Dynavax has GSK's shingles vaccine in its sights Big pharma group GSK has been ruling the market for shingles vaccines for many years, but little Dynavax wants to knock off its crown.
News Iterum brings first oral penem antibiotic to US market Iterum has launched Orlynvah as a treatment for uncomplicated urinary tract infections (uUTIs), the first oral option in the go-to penem class.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
